The COVID-19 pandemic has modified the management of urothelial carcinoma (UC). Eighteen months after the onset of the pandemic, a scoping narrative review was able to state that radical cystectomy for UC should not be delayed beyond 10 weeks when neoadjuvant chemotherapy (NAC) was administered and 12 weeks when it was not. NAC should be considered when imminent chemotherapy cannot be performed. Early cystectomy should not be delayed when indicated for patients with high-risk non-MIBC. Patients with non-MIBC should still receive their induction doses of intravesical instillations. Diagnostic cystoscopy should not be deferred in symptomatic patients. Surgical management of upper tract urothelial carcinoma (UTUC) allows for a wider deferral interval.
【저자키워드】 COVID-19, Urothelial cancer, neoadjuvant chemotherapy, diagnostic cystoscopy, radical cystectomy, 【초록키워드】 pandemic, COVID-19 pandemic, Chemotherapy, Symptomatic patients, management, Patient, dose, Administered, NAC, performed, indicated, receive, intravesical, 【제목키워드】 pandemic, Clinical practice, urothelial carcinoma,